ALX Oncology Holdings Statistics
Total Valuation
ALXO has a market cap or net worth of $34.97 million. The enterprise value is -$75.81 million.
Important Dates
The last earnings date was Thursday, March 6, 2025, after market close.
| Earnings Date | Mar 6, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
ALXO has 53.38 million shares outstanding. The number of shares has increased by 21.37% in one year.
| Current Share Class | 53.38M |
| Shares Outstanding | 53.38M |
| Shares Change (YoY) | +21.37% |
| Shares Change (QoQ) | +0.21% |
| Owned by Insiders (%) | 2.40% |
| Owned by Institutions (%) | 52.41% |
| Float | 32.34M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.31 |
| P/TBV Ratio | 0.31 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.26, with a Debt / Equity ratio of 0.15.
| Current Ratio | 7.26 |
| Quick Ratio | 6.95 |
| Debt / Equity | 0.15 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -82.40 |
Financial Efficiency
Return on equity (ROE) is -88.91% and return on invested capital (ROIC) is -53.97%.
| Return on Equity (ROE) | -88.91% |
| Return on Assets (ROA) | -45.62% |
| Return on Invested Capital (ROIC) | -53.97% |
| Return on Capital Employed (ROCE) | -110.20% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.69M |
| Employee Count | 80 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -94.26% in the last 52 weeks. The beta is 1.01, so ALXO's price volatility has been similar to the market average.
| Beta (5Y) | 1.01 |
| 52-Week Price Change | -94.26% |
| 50-Day Moving Average | 1.12 |
| 200-Day Moving Average | 2.50 |
| Relative Strength Index (RSI) | 33.25 |
| Average Volume (20 Days) | 1,382,974 |
Short Selling Information
The latest short interest is 6.39 million, so 11.97% of the outstanding shares have been sold short.
| Short Interest | 6.39M |
| Short Previous Month | 5.89M |
| Short % of Shares Out | 11.97% |
| Short % of Float | 19.75% |
| Short Ratio (days to cover) | 4.71 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -142.47M |
| Pretax Income | -166.20M |
| Net Income | -134.85M |
| EBITDA | -141.60M |
| EBIT | -142.47M |
| Earnings Per Share (EPS) | -$2.58 |
Full Income StatementBalance Sheet
The company has $127.76 million in cash and $16.98 million in debt, giving a net cash position of $110.78 million or $2.08 per share.
| Cash & Cash Equivalents | 127.76M |
| Total Debt | 16.98M |
| Net Cash | 110.78M |
| Net Cash Per Share | $2.08 |
| Equity (Book Value) | 113.62M |
| Book Value Per Share | 2.14 |
| Working Capital | 115.85M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$121.91 million and capital expenditures -$447,000, giving a free cash flow of -$122.36 million.
| Operating Cash Flow | -121.91M |
| Capital Expenditures | -447,000 |
| Free Cash Flow | -122.36M |
| FCF Per Share | -$2.29 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |